| Literature DB >> 33566210 |
Asaf Tzachor1, Or Rozen2, Soliman Khatib3, Sophie Jensen4, Dorit Avni5.
Abstract
An array of infections, including the novel coronavirus (SARS-CoV-2), trigger macrophage activation syndrome (MAS) and subsequently hypercytokinemia, commonly referred to as a cytokine storm (CS). It is postulated that CS is mainly responsible for critical COVID-19 cases, including acute respiratory distress syndrome (ARDS). Recognizing the therapeutic potential of Spirulina blue-green algae (Arthrospira platensis), in this in vitro stimulation study, LPS-activated macrophages and monocytes were treated with aqueous extracts of Spirulina, cultivated in either natural or controlled light conditions. We report that an extract of photosynthetically controlled Spirulina (LED Spirulina), at a concentration of 0.1 µg/mL, decreases macrophage and monocyte-induced TNF-α secretion levels by over 70% and 40%, respectively. We propose prompt in vivo studies in animal models and human subjects to determine the putative effectiveness of a natural, algae-based treatment for viral CS and ARDS, and explore the potential of a novel anti-TNF-α therapy.Entities:
Keywords: Anti TNF-α therapy; Biotechnology; COVID-19; Cytokine storm; Immunology; Spirulina
Mesh:
Substances:
Year: 2021 PMID: 33566210 PMCID: PMC7874025 DOI: 10.1007/s10126-021-10020-z
Source DB: PubMed Journal: Mar Biotechnol (NY) ISSN: 1436-2228 Impact factor: 3.619